We attended CROI, the traditional Conference on Retroviruses and Opportunistic Infections, held this year in Denver, USA. We participated in the presentation of results from the PURPOSE 2 and ARTISTRY studies, among other exchange activities with colleagues from around the world.
We are proud to be part of these cutting-edge research and innovation initiatives.
Follow-up from the PURPOSE study confirms the extraordinary efficacy of a medication administered subcutaneously every six months to prevent HIV acquisition in at-risk individuals.
The ARTISTRY study—published in The Lancet in conjunction with its presentation at this conference—shows that a simplified one-tablet-a-day regimen facilitates treatment for people who had been on complex regimens due to long-term infection (over 25 years) and exposure to multiple treatments. These long-acting drugs promise to revolutionize HIV prevention and treatment.
